Akorn's ANDA for Diltiazem Hydrochloride Injection for high blood pressure, chest pain, approved

By Lisa Kerner

Charlotte, N.C., July 24 - Akorn, Inc. said it received Food and Drug Administration approval for its abbreviated New Drug Application for Diltiazem Hydrochloride Injection, 5 mg/mL in 25 mL vials for the treatment of high blood pressure and to control chest pain.

Akorn expects to launch Diltiazem in the fourth quarter, officials said.

This is the seventh product approval for the company this year.

Akorn, based in Buffalo Grove, Ill., manufactures and markets sterile specialty pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.